This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 115/1/114    most recent CIRCULATIONAHA.106.179294v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buse, J. B. Articles by Stone, N. J. Search for Related Content PubMed PubMed Citation Articles by Buse, J. B. Articles by Stone, N. J. Pubmed/NCBI databases Medline Plus Health Information Diabetes Complications Related Collections Nutrition Lipids Primary prevention Exercise testing Risk Factors Other hypertension Type 1 diabetes Type 2 diabetes Other diabetes Glucose intolerance AHA Statements and Guidelines Exercise/exercise testing/rehabilitation

(Circulation. 2007;115:114-126.)
© 2007 American Heart Association, Inc.

AHA/ADA Scientific Statement

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus

A Scientific Statement From the American Heart Association and the American Diabetes Association

John B. Buse, MD, PhD, Co-chair; Henry N. Ginsberg, MD, FAHA, Co-chair; George L. Bakris, MD, FAHA; Nathaniel G. Clark, MD, MS, RD; Fernando Costa, MD, FAHA; Robert Eckel, MD, FAHA; Vivian Fonseca, MD; Hertzel C. Gerstein, MD, MSc, FRCPC; Scott Grundy, MD, FAHA; Richard W. Nesto, MD, FAHA; Michael P. Pignone, MD, MPH; Jorge Plutzky, MD; Daniel Porte, MD; Rita Redberg, MD, FAHA; Kimberly F. Stitzel, MS, RD; Neil J. Stone, MD, FAHA

The American Heart Association (AHA) and the American Diabetes Association (ADA) have each published guidelines for cardiovascular disease prevention: The ADA has issued separate recommendations for each of the cardiovascular risk factors in patients with diabetes, and the AHA has shaped primary and secondary guidelines that extend to patients with diabetes. This statement will attempt to harmonize the recommendations of both organizations where possible but will recognize areas in which AHA and ADA recommendations differ.

Key Words: AHA Scientific Statement • cardiovascular diseases • diabetes mellitus • primary prevention

This article has been cited by other articles:

				S. J. Lewis, K. M. Fox, M. F. Bullano, S. Grandy, and for the SHIELD Study Group Knowledge of Heart Disease Risk Among SHIELD Respondents With Dyslipidemia Circ Cardiovasc Qual Outcomes, May 1, 2009; 2(3): 207 - 212. [Abstract] [Full Text] [PDF]

				S. Tavintharan, Ning Cheung, Su Chi Lim, W. Tay, A. Shankar, E. Shyong Tai, and T. Y. Wong Prevalence and risk factors for peripheral artery disease in an Asian population with diabetes mellitus Diabetes and Vascular Disease Research, April 1, 2009; 6(2): 80 - 86. [Abstract] [PDF]

				U.S. Preventive Services Task Force Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med, March 17, 2009; 150(6): 396 - 404. [Abstract] [Full Text] [PDF]

				CORONARY REVASCULARIZATION WRITING GROUP, M. R. Patel, G. J. Dehmer, J. W. Hirshfeld, P. K. Smith, and J. A. Spertus ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: A Report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography Circulation, March 10, 2009; 119(9): 1330 - 1352. [Full Text] [PDF]

				M. R. Patel, G. J. Dehmer, J. W. Hirshfeld, P. K. Smith, and J. A. Spertus ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: A Report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography J. Am. Coll. Cardiol., February 10, 2009; 53(6): 530 - 553. [Full Text] [PDF]

				J. S. Skyler, R. Bergenstal, R. O. Bonow, J. Buse, P. Deedwania, E. A.M. Gale, B. V. Howard, M. S. Kirkman, M. Kosiborod, P. Reaven, et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association J. Am. Coll. Cardiol., January 20, 2009; 53(3): 298 - 304. [Full Text] [PDF]

				J. S. Skyler, R. Bergenstal, R. O. Bonow, J. Buse, P. Deedwania, E. A.M. Gale, B. V. Howard, M. S. Kirkman, M. Kosiborod, P. Reaven, et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association Circulation, January 20, 2009; 119(2): 351 - 357. [Full Text] [PDF]

				J. S. Skyler, R. Bergenstal, R. O. Bonow, J. Buse, P. Deedwania, E. A.M. Gale, B. V. Howard, M. S. Kirkman, M. Kosiborod, P. Reaven, et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Diabetes Care, January 1, 2009; 32(1): 187 - 192. [Full Text] [PDF]

				J.-C. Fruchart, F. M Sacks, M. P Hermans, G. Assmann, W V. Brown, R. Ceska, M J. Chapman, P. M Dodson, P. Fioretto, H. N Ginsberg, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients Diabetes and Vascular Disease Research, November 1, 2008; 5(4): 319 - 335. [Abstract] [PDF]

				J. M. Jakicic, B. H. Marcus, W. Lang, and C. Janney Effect of Exercise on 24-Month Weight Loss Maintenance in Overweight Women Arch Intern Med, July 28, 2008; 168(14): 1550 - 1559. [Abstract] [Full Text] [PDF]

				U. Campia and J. A. Panza Flavanol-rich cocoa a promising new dietary intervention to reduce cardiovascular risk in type 2 diabetes? J. Am. Coll. Cardiol., June 3, 2008; 51(22): 2150 - 2152. [Full Text] [PDF]

				A. Y. Gasparyan, T. Watson, and G. Y.H. Lip The Role of Aspirin in Cardiovascular Prevention: Implications of Aspirin Resistance J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1829 - 1843. [Abstract] [Full Text] [PDF]

				T. K. Schramm, G. H. Gislason, L. Kober, S. Rasmussen, J. N. Rasmussen, S. Z. Abildstrom, M. L. Hansen, F. Folke, P. Buch, M. Madsen, et al. Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk: A Population Study of 3.3 Million People Circulation, April 15, 2008; 117(15): 1945 - 1954. [Abstract] [Full Text] [PDF]

				A. Elis, L. Rosenmann, G. Chodick, A.D. Heymann, E. kokia, and V. Shalev The association between glycemic, lipids and blood pressure control among Israeli diabetic patients QJM, April 1, 2008; 101(4): 275 - 280. [Abstract] [Full Text] [PDF]

				R. B. Goldberg and T. A. Jacobson Effects of Niacin on Glucose Control in Patients With Dyslipidemia Mayo Clin. Proc., April 1, 2008; 83(4): 470 - 478. [Abstract] [Full Text] [PDF]

				S. E. Inzucchi and D. K. McGuire New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond Circulation, January 29, 2008; 117(4): 574 - 584. [Abstract] [Full Text] [PDF]

				D. K. McGuire and S. E. Inzucchi New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications Circulation, January 22, 2008; 117(3): 440 - 449. [Full Text] [PDF]

				T. Amano, T. Matsubara, T. Uetani, M. Nanki, N. Marui, M. Kato, T. Yoshida, K. Arai, K. Yokoi, H. Ando, et al. Abnormal glucose regulation is associated with lipid-rich coronary plaque: relationship to insulin resistance. J. Am. Coll. Cardiol. Img., January 1, 2008; 1(1): 39 - 45. [Abstract] [Full Text] [PDF]

				J. J. Bax, L. H. Young, R. L. Frye, R. O. Bonow, H. O. Steinberg, and E. J. Barrett Screening for Coronary Artery Disease in Patients With Diabetes Diabetes Care, October 1, 2007; 30(10): 2729 - 2736. [Abstract] [Full Text] [PDF]

				A. Zambon and K. Cusi The role of fenofibrate in clinical practice Diabetes and Vascular Disease Research, September 1, 2007; 4(3_suppl): S15 - S20. [Abstract] [PDF]

				S. M. Donahoe, G. C. Stewart, C. H. McCabe, S. Mohanavelu, S. A. Murphy, C. P. Cannon, and E. M. Antman Diabetes and Mortality Following Acute Coronary Syndromes JAMA, August 15, 2007; 298(7): 765 - 775. [Abstract] [Full Text] [PDF]

				J. Lewis Treating Diabetic Nephropathy: Unfinished Success Is Not Failure Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 407 - 409. [Full Text] [PDF]